Clinical trials: Blood Sample
Leukemia, Chronic Myelogenous Leukemia
Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients
The goal of this clinical research study is to find out if IL-11 (NeumegaTM) may increase the platelet count in patients with Chronic myeloid leukemia (CML) who develop low platelet counts while receiving therapy with imatinib…
- Conditions
- Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia
- Trial name
- NCT00493181
- Testing
- Interleukin-11 (IL-11 or Neumega)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Diabetes
Evaluation of an Karajishi TS Investigational Blood Glucose Monitoring System
The purpose of this study was to determine if subjects who have diabetes can operate the Investigational Blood Glucose Monitoring System (BGMS) with no training and obtain valid glucose results.
- Trial name
- NCT02041377
- Testing
- Karajishi TS Investigational Blood Glucose Monitoring System
- Where
- 2 sites in United States
- Volunteers
- 134 people
- Sponsor
- Ascensia Diabetes Care
Hepatitis B
A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults
The objective of this study is to evaluate the immunogenicity and Anti-HBV antibody persistence of hepatitis B vaccine with different doses and schedules.
- Trial name
- NCT02203357
- Testing
- Hepatitis B vaccine
- Where
- China
- Volunteers
- 353 people
- Sponsor
- Peking University
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload.
- Conditions
- Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01159067
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Hepatitis C, Chronic
Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)
This study will evaluate the safety, tolerability, and antiviral activity of grazoprevir (MK-5172) when administered in combination with peginterferon alfa-2b (Peg-IFN) and ribavirin (RBV) in treatment-naïve (TN) participants…
- Trial name
- NCT01353911
- Testing
- Grazoprevir, Boceprevir, Peg-interferon alfa-2b
- Volunteers
- 368 people
- Sponsor
- Merck Sharp & Dohme LLC
Acquired Immunodeficiency Syndrome, HIV Infections
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
This study is to characterize the effect of cobicistat-based regimens on parameters of renal function in participants with HIV infection and who have mild to moderate renal impairment, and to assess the safety and tolerability of…
- Trial name
- NCT01363011
- Testing
- E/C/F/TDF, COBI, ATV
- Where
- 51 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01816971
- Testing
- dexamethasone, carfilzomib, lenalidomide
- Where
- 5 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- University of Chicago
HIV Infections, Hepatitis C
Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
HIV and hepatitis C virus (HCV) infection are diseases that share the same risk factors and routes of transmission. For this reason, many people infected with HIV are also infected with HCV.
- Trial name
- C_ASCENT (NCT02194998)
- Testing
- Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV)
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 46 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Myeloma
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
To evaluate whether using the drug bortezomib at the start of remission will prevent relapse for a longer period of time.
- Trial name
- 2007-77 (NCT00657553)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Arkansas
Moderate to Severe Hypertension
Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension
This study will compare the blood pressure (BP) lowering effect of the combination of aliskiren/amlodipine 300/10 mg versus amlodipine 10 mg monotherapy in patients with moderate to severe hypertension by testing the hypothesis…
- Trial name
- NCT00841672
- Testing
- Aliskiren/amlodipine 300/10 mg tablet, Amlodipine 10 mg capsule
- Where
- 6 sites in Germany, Philippines and 4 more
- Volunteers
- 485 people
- Sponsor
- Novartis
Liver Fibrosis, Hepatitis C
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
- Conditions
- Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
- Trial name
- NCT01707472
- Testing
- Simtuzumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
Congenital Bleeding Disorder, Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
This trial is conducted in Asia, Europe, and North and South America. The aim of this clinical trial is to investigate the safety and efficacy of turoctocog alfa (recombinant factor VIII, rFVIII (N8)) in male previously treated…
- Trial name
- guardian™ 3 (NCT01138501)
- Testing
- turoctocog alfa
- Where
- 38 sites in United States, Brazil and 11 more
- Volunteers
- 65 people
- Sponsor
- Novo Nordisk A/S
HIV/AIDS, Adherence
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
Development of Real-Time Antiretroviral Therapy Adherence Intervention in Uganda (The Wisepill Study).
- Trial name
- NCT01957865
- Testing
- Fixed SMS, real-time monitoring, Triggered SMS, real-time monitoring
- Where
- Uganda
- Volunteers
- 63 people
- Sponsor
- Massachusetts General Hospital
Anal Cancer, High-grade Squamous Intraepithelial Lesion
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
The randomized phase of the trial compared topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL).
- Conditions
- Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
- Trial name
- ANCHOR (NCT02135419)
- Testing
- imiquimod, fluorouracil, infrared photocoagulation therapy
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 4,446 people
- Sponsor
- AIDS Malignancy Consortium
Healthy
Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years of age
- Trial name
- NCT01005407
- Testing
- Engerix-B
- Where
- 32 sites in United States, Canada
- Volunteers
- 2,452 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Thrombocytopenia
Study of the Effect of Differing Platelet Transfusion Times in Neonates
To evaluate changes in platelet counts and hemodynamics between "rapid" and "long" platelet infusion groups.
- Trial name
- NCT00948792
- Testing
- Short platelet transfusion, Long platelet transfusion
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Oklahoma
Multiple Myeloma
HD Melphalan and SCT in Patients With IGDD or LCDD
RATIONALE: Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00681044
- Testing
- filgrastim, melphalan, Stem Cell Infusion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Boston Medical Center
Hepatitis B, Chronic
A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531
This sponsor-open, investigator- and participant-blinded, multi-center study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7020531 in healthy participants and in participants with chronic…
- Trial name
- NCT02956850
- Testing
- RO7020531
- Where
- 18 sites in Bulgaria, Hong Kong and 6 more
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
The aim of the study is to confirm efficacy and safety of treatment with 600 mg of BID BI 207127 in combination with 120 mg QD FDV and RBV for 16 or 24 weeks in target chronically infected HCV GT1b treatment naïve patients…
- Trial name
- NCT01728324
- Testing
- Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment
- Where
- 109 sites in United States, Australia and 10 more
- Volunteers
- 496 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes, High Blood Sugar
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
This is a 24-week randomised, multi-centre phase III study to evaluate the efficacy and safety of dapagliflozin as monotherapy in Japanese subjects with Type 2 diabetes mellitus who have inadequate glycemic control with diet and…
- Trial name
- NCT01294423
- Testing
- Dapagliflozin
- Where
- 26 sites in Japan
- Volunteers
- 261 people
- Sponsor
- AstraZeneca